Trial Profile

A phase 1 clinical trial of NTX 250

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 21 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NTX-250 (Primary)
Indications Cancer
Focus Adverse reactions

Most Recent Events

19 Apr 2023 According to a Nutcracker Therapeutics media release, this trial is expected to initiate by early 2024.
21 Nov 2022 New trial record
11 Nov 2022 According to a Nutcracker Therapeutics media release, this trial is planned for 2023, pending the clearance of an Investigational New Drug application by the Food and Drug Administration.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com